Our Goal Is
To Be A Pioneer
In Biological Medicines!

Led by the Gamaleya Epidemiology and Microbiology Research Center, which has over 40 years of experience in adenoviral vectors, production processes of the first adenovector-based COVID-19 vaccine were initiated in Turkey.

ABOUT VISCORAN
VISCORAN

In the field of biotechnology, by establishing business partnerships in international markets for Viscoran-identified innovative products, we carry out post-technology transfer production, sales-marketing, import and export activities.

GET INFO
CLINICAL STUDIES REVIEW
CLINICAL STUDIES

In order to obtain local efficacy and safety data in the drug / medical product development process, Viscoran conducts clinical research in Turkey.

REVIEW
OUR BUSINESS PARTNERS REVIEW
OUR BUSINESS PARTNERS

Joint marketing and licensing agreements are agreed upon in order to enhance the product range with innovative and advanced technology products.

REVIEW
COVID-19 Vaccine

COVID-19 vaccine based on human Adenovirus vectors, pioneered by Viscoran in Turkey; It is a platform developed by the Russian Gamaleya Epidemiology and Microbiology Research Center and has been studied since the 1980s.

DISCOVER MORE
Biotechnological Medicines

Biotechnology is a multidisciplinary branch of science and technology that uses living organisms or systems to obtain useful products, improving the quality of human life and furthering product development as a result of the interactions between biological sciences and technology, such as biology, biochemistry, microbiology.

Review

BIOTECHNOLOGY

We rely on biotechnology and our expert team to respond and find solutions to global health problems.
1.
THE FIRST ADENOVIRAL VECTOR-BASED VACCINE IN THE WORLD

Partner In Turkey

Viscoran
INNOVATIVE PRODUCTS

We respond to changing needs with innovative products.

04.06.2021
EMA Expresses No Significant Concerns About Sputnik V Production or Clinical Trials, RDIF Says

ST. PETERSBURG (Sputnik) - The European Medicines Agency (EMA), which is currently studying Russia's Sputnik V vaccine against COVID-19...

View
01.06.2021
Russian Ambassador: SputnikV efficacy at 91.8% in elderly, EU to examine vaccine this month

The first Russian vaccine against COVID-19, SputnikV, named after the first artificial space satellite in history, has been approved so far in 23 countries...

View
01.05.2021
Sputnik V vaccine has 91.6% efficacy against symptomatic Covid, Russian trial suggests

The Sputnik V vaccine, which has been the subject of scepticism since Russia began using it last year before trials had ended, is 91.6% effective..

View

Innovative Solutions
For A Healthy Life

Contact us;
info@viscoranilac.com